Absci Corp

Absci Corporation (NASDAQ: ABSI) is a clinical-stage biopharmaceutical company leveraging artificial intelligence to develop differentiated antibody therapeutics. The company operates through its proprietary Integrated Drug Creation platform, which combines generative AI models with rapid laboratory validation in a continuous feedback loop designed to accelerate drug discovery and development.

The company's core technology platform, Origin-1, represents a de novo AI model capable of designing full-length monoclonal antibodies against previously uncharacterized epitopes, or "zero-prior" epitopes. This platform integrates three key components: data generation through high-throughput wet-lab capabilities spanning 77,000 square feet of combined wet-lab and dry-lab facilities, AI-guided design using generative models and lead optimization algorithms, and rapid validation through laboratory testing. The lab-in-the-loop approach enables the company to advance product candidates from AI design to investigational new drug status in approximately two years at an estimated investment of $15 million per program, compared to industry averages of four to six years and costs exceeding $50 million.

Absci's pipeline includes two internally developed programs in clinical development. ABS-201, the lead candidate, is an anti-prolactin receptor antibody in Phase 1/2a development for androgenetic alopecia and planned Phase 2 development for endometriosis. ABS-101, targeting inflammatory bowel disease, completed Phase 1 testing and is being considered for partnership. The company also advances several preclinical programs including ABS-301 and ABS-501 in oncology and immunology indications.

The company operates a dual business model combining internal pipeline development with strategic partnerships. Through drug creation collaborations, Absci partners with biopharmaceutical companies including Merck, AstraZeneca, and Almirall, generating revenue through upfront fees, research funding, milestone payments, and royalties. The company website is www.absci.com. Absci qualifies as a smaller reporting company and emerging growth company under SEC definitions, with operations concentrated in its primary research facilities.